Psychedelics are pursuing FDA clinical pathways much more than cannabis did
Dr. Linda Strauss · Psilocybin Breaks Neural Connections - Then Therapy Rewires Them · Apr 28, 2022 · at 8:57
Dr. Linda Strauss is a clinical trial expert and co-founder of EI Ventures, discussing the strategic differences between the cannabis and psychedelic medical sectors.
0:00 / 0:14exact quote · 14.6s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“I see A lot more activity on the regulated pathway, whereas cannabis has clearly taken the adult use pathway with very few products that have moved into that space with Epidiolex being the exception to the rule.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Linda Strauss
Psilocybin breaks neural connections so follow-on psychotherapy can rewire them
“So if you think about a psychedelic trip, you can imagine that the psilocybin breaks apart those neural connections and then follow on psychotherapy Will reconnect them in a, air quote, healthier way.”
The FDA will not approve psychedelic medicines without accompanying talk therapy
“I don't see the FDA, by the way, Sean, a hundred percent. I don't see the FDA approving any of this that isn't in combination with some form of talk therapy.”
Serious psilocybin side effects are linked to 5-HT receptor binding
“Now there is some side effects, serious side effects that have emerged with psilocybin due to its binding to the five HT The two B receptor. It's either the two A receptor, the two B receptor.”
Areas with cannabis dispensaries see lower rates of opioid use disorder
“There's a great study, I want to say it's out of UC Davis, that's literally shown a slightly different crisis, but the opioid overuse, you know, substance abuse diseases, an opioid use that's shown that in areas where there's cannabis dispensaries, there's a l…”